All-comers versus enrichment design strategy in phase II trials

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 658-660

  Mandrekar, Sumithra J ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adaptive; All comers; Biomarker; Enrichment; Phase II; Randomized

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; EXPERIMENTAL DESIGN; FEASIBILITY STUDY; HUMAN; MEDICAL LITERATURE; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; VALIDITY;

CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTATIONAL BIOLOGY; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 79952994872     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820e17cb     Document Type: Article

References (11)

1. Mandrekar SJ, Qin R, Sargent DJ. Model-based phase I designs incor-porating toxicity and efficacy for single and dual agent drug combina-tions: methods and challenges. Stat Med 2010;29:1077-1083.
2. Hallberg B, Palmer RH. Crizotinib\latest champion in the cancer wars? NEngl JMed 2010;363:1760-1762.
3. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. NEngl JMed 2010;363:1693-1703.
4. Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol 2010;5:932-934.
5. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive bio-marker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-4034.
6. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
7. Zhou X, Liu S, Kim ES. Bayesian adaptive design for targeted therapy development in lung cancer-a step towards personalized medicine. Clin Trials 2008;5:181-193.
8. Kim ES, Herbst RS, Lee JJ, et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimina-tion): personalizing therapy for lung cancer [abstract]: 101 Annual Conference of American Association for Cancer Research, Washington, DC, 2010, abstract LB-1.
9. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004;10:6759-6763. (Pubitemid 39383023)
10. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. JNatl Cancer Inst 2009;101:1-7.
11. Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol 2010;28:2925-2935.